Capricor Therapeutics, Inc. CAPR
8.87 USD -0.98 (-9.95%)
At closeNov 10, 2026, 7:59 PM EST
9.26 +0.39 +4.40%
After hours · Nov 10, 7:59 PM ET
8.85 Day range 10.06
3.85 52-week range 35.34
- YTD
- -69.27%
- 1 year
- +59.53%
News
seekingalpha.com Capricor Therapeutics, Inc. (CAPR) Q3 2026 Earnings Call Transcript Capricor Therapeutics, Inc. (CAPR) Q3 2026 Earnings Call Transcript
marketbeat.com Capricor Therapeutics Q3 Earnings Call Highlights Capricor Therapeutics NASDAQ: CAPR is awaiting a Nov. 22 Food and Drug Administration decision on Deramiocel for Duchenne muscular dystrophy, as the company prepares for a potential launch while…
benzinga.com Capricor Therapeutics Q3 2026 Earnings Call Transcript Capricor Therapeutics (NASDAQ:CAPR) held its third-quarter earnings conference call on Tuesday. Below is the complete transcript from the call.This transcript is brought to you by Benzinga APIs. For…
benzinga.com Capricor Therapeutics Q3 EPS $(0.73) Misses $(0.05) Estimate Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.05) by 1360 percent. This is a 35.19 percent decrease over losses…
globenewswire.com Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare…
globenewswire.com Capricor's HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare…
globenewswire.com Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10 SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare…
benzinga.com Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket Inovio shares surged 230% premarket after FDA accelerated Voceryq approval; ClearOne and 22nd Century gained, while RedCloud fell 33.5%.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) stock moved upwards by 292.6% to $2.37 during Friday's after-market session. The market value of their outstanding shares is at $79.8 million. Capricor…
seekingalpha.com Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript
marketbeat.com Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears Capricor Therapeutics NASDAQ: CAPR presented updated clinical data for deramiocel in Duchenne muscular dystrophy, or DMD, including two-year open-label extension results from its Phase III HOPE-3…
benzinga.com What's Going On With Capricor Therapeutics Stock Monday? Capricor Therapeutics (CAPR) shares top-line HOPE-3 extension data for Deramiocel in DMD ahead of its Nov 22 FDA PDUFA date.
benzinga.com Capricor Therapeutics Presents New Data From Ongoing HOPE-3 OLE Study For Its Lead Asset, Deramiocel, For Treatment Of Upper Limb Impairment In DMD, At 31st Annual Congress Of WMS In Hiroshima -24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year--At 24 Months, Both Groups Showed Slower Decline…
globenewswire.com Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress -24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year- -At 24 Months, Both Groups Showed Slower…
schaeffersresearch.com Inflation Breather Could Help Stocks Finish Q3 Strong Stocks are higher to end September and Q3, as inflation data comes in cooler than expected
benzinga.com Capricor Therapeutics Stock Surges: What's Going On? Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are trading higher Wednesday morning following the release of positive long-term clinical data for its lead cellular therapy.
benzinga.com Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday U.S. stocks rose as Nasdaq gained 100+ points; HPE jumped 5.1% on stronger networking guidance and a Vultr AI rack order.
benzinga.com Why FingerMotion Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket FingerMotion jumped 18.1% premarket after agreeing to buy Newbit Technology for $2.3M cash; NewGenIvf led gainers at 187.2%, while Silexion fell 16.6%.
businesswire.com CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026 NEW YORK--(BUSINESS WIRE)---- $CAPR #CAPR--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. (“Capricor” or the…
globenewswire.com Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Capricor Therapeutics, Inc. Lawsuit - CAPR A securities class action alleges Capricor Therapeutics told investors its Phase 3 HOPE-3 results were statistically significant while allegedly omitting that the final statistical analysis plan was…
businesswire.com CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $CAPR--CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law.
globenewswire.com CAPR Investor Lawsuit: Capricor Therapeutics Sued for Securities Fraud on behalf of Investors with Losses – Contact BFA Law by September 28 Court Deadline NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc.…
gurufocus.com CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS LawPR NewswireLOS ANGELES, Sept. 28, 2026LOS ANGELES, Sept
gurufocus.com Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPRPR NewswireNEW YORK, Sept. 28, 2026NEW Y
prnewswire.com CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES, Sept. 28, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor…
prnewswire.com Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR NEW YORK, Sept. 28, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR ) for violations…
newsfilecorp.com CAPR INVESTOR DEADLINE: Rosen Law Firm Reminds Capricor Therapeutics, Inc. Investors of September 28 Lead Plaintiff Deadline in Securities Class Action New York, New York--(Newsfile Corp. - September 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR)…
newsfilecorp.com CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline San Francisco, California--(Newsfile Corp. - September 27, 2026) - Hagens Berman Sobol Shapiro LLP-a national plaintiffs' rights law firm with a premier securities practice group-notifies investors…
newsfilecorp.com CAPR DEADLINE: ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 28 Deadline in Securities Class Action - CAPR New York, New York--(Newsfile Corp. - September 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR)…
globenewswire.com CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline SAN FRANCISCO, Sept. 26, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities practice group—notifies investors in Capricor…
benzinga.com B. Riley Securities Upgrades Capricor Therapeutics to Buy, Raises Price Target to $21 B. Riley Securities analyst Madison El-Saadi upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Buy and raises the price target from $5 to $21.
benzinga.com Piper Sandler Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $25 Piper Sandler analyst Edward Tenthoff upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $2 to $25.
benzinga.com Yext Posts Upbeat Q2 Earnings, Joins Fervo Energy, MiniMed Group And Other Big Stocks Moving Higher On Tuesday U.S. stocks were lower, with the Nasdaq Composite falling around 1% on Tuesday. Shares of Yext Inc (NYSE:YEXT) rose sharply after the company reported better-than-expected second-quarter earnings.…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion. SCYNEXIS (NASDAQ:SCYX) stock…
benzinga.com Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings and raising forecasts. Other top gainers include Kanzhun, Capricor Therapeutics, Semtech Corp, and…
benzinga.com Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
benzinga.com Why Is Capricor Therapeutics Stock Trading Higher on Monday? Capricor stock rises as FDA extends its deramiocel review to Nov. 22 following new Phase 3 HOPE-3 data and an advisory panel setback.- benzinga.com Capricor Therapeutics Says FDA Extends PDUFA Target Action Date For Its BLA For Deramiocel, Investigational Cell Therapy For Duchenne Muscular Dystrophy, From August 22 To November 22 – New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication –SAN DIEGO, Aug. 24, 2026 (GLOBE…
benzinga.com Activist Investor Sounds Alarm on Capricor’s Cash Burn Kaos Capital demands a governance reset and cash preservation at Capricor Therapeutics (NASDAQ: CAPR) as expenses rise.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Kaos Capital Plans To Nominate Two Independent Directors On Capricor Therapeutics' Board; To Seek Board-Led M&A, Strategic Alternatives Committee Kaos Capital Ltd. ("Kaos Capital," "we," or "us"), a significant and growing shareholder of Capricor Therapeutics, Inc. (NASDAQ:CAPR) ("Capricor" or the "Company"), today issued a
benzinga.com H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday H World Group (HTHT) beats earnings and raises sales guidance, shares jump 8.1%. Other big gainers include ANGX, ARGX, and MESO.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.
benzinga.com Capricor Therapeutics Remains Optimistic about Deramiocel FDA Approval Capricor Therapeutics highlights Deramiocel's FDA review, commercial readiness, and cash position of $approximately $237.9 million.
benzinga.com This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday Wall Street analysts revised their ratings for top stocks. Visit benzinga.com/analyst-stock-ratings for all changes, including upgrades and downgrades.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market session. The company's market cap stands at $243.8 million. As per the news, the Q2 earnings report…- benzinga.com Market-Moving News for August 14th AMAT: -5% | Applied Materials shares are trading lower after the company reported Q3 financial results. Weakness may be related to elevated investor expectations. AKAN: 100% | Akanda shares are…
benzinga.com Cantor Fitzgerald Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $28 Cantor Fitzgerald analyst Kristen Kluska upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $3.5 to $28.
benzinga.com Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results and issuing FY26 revenue guidance above estimates.- benzinga.com Capricor Therapeutics (CAPR) Shares Soar Over 67% After Hours: Here's Why Capricor Therapeutics shares surged 67.22% after hours following quarterly results and an update on the FDA review of its application.